首页> 外文OA文献 >Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

【2h】

Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

机译：在阿尔茨海默病（REBRAND）研究中重新培养溴杉木（REBRAND）研究：随机安慰剂对照双盲比较试验和开放标签扩展试验，探讨溴杉木在阿尔茨海默病与PRESENILIN 1（PSEN1）突变中的安全性和有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Takayuki Kondo; Haruhiko Banno; Taro Okunomiya; Yoko Amino; Kayoko Endo; Akiyoshi Nakakura; Ryuji Uozumi; Akemi Kinoshita; Harue Tada; Satoshi Morita; Hidehiro Ishikawa; Akihiro Shindo; Ken Yasuda; Yosuke Taruno; Takakuni Maki; Takashi Suehiro; Kohji Mori; Manabu Ikeda; Koji Fujita; Yuishin Izumi; Kazutomi Kanemaru; Kenji Ishii; Kazue Shigenobu; Yumiko Kutoku; Yoshihide Sunada; Shinobu Kawakatsu; Shunji Shiota; Toshifumi Watanabe; Osamu Uchikawa; Ryosuke Takahashi; Hidekazu Tomimoto; Haruhisa Inoue;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): A randomised, double-blind, placebo-controlled phase 2 trial [J] . WilkinsonD., WindfeldK., Colding-J?rgensenE. Lancet Neurology . 2014,第11期

机译：5-HT6受体拮抗剂伊洛哌丁在中度阿尔茨海默氏病（LADDER）患者中的安全性和有效性：一项随机，双盲，安慰剂对照的2期临床试验
2. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase Ma, double-blind, randomised, placebo-controlled trial [J] . Lars Lannfelt, Kaj Blennow, HenrikZetterberg, Lancet Neurology . 2008,第9期

机译：PBT2靶向Abeta作为阿尔茨海默氏病改良疗法的安全性，有效性和生物标志物研究：Ma期，双盲，随机，安慰剂对照试验
3. A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase [J] . Manning Donald C., Gimbel Joseph, Wertz Robert, Pain medicine : . 2017,第3期

机译：Lenalal族疼痛中Lenalidomide在Lenalal突出疼痛中的一期随机，双盲，安慰剂控制的安全性和疗效研究A II期随机，双盲，安慰剂对照安全性和Lenalidomide的疗效研究在腰部疼痛的长期开放标签扩展阶段
4. A Randomized, Placebo-Controlled Study of the Efficacy of Cognitive Intervention on Elderly People and on Patient's with Alzheimer's Disease [C] . J.J. Yanguas, C. Buiza, I. Etxeberria, International Conference on Computers Helping People with Special Needs(ICCHP 2006); 20060711-13; Linz(AT) . 2006

机译：认知干预对老年人和阿尔茨海默氏病患者疗效的随机，安慰剂对照研究
5. Investigating Nutritional Status in Moderate to Severe Alzheimer's Disease Patients Enrolled in a Randomized Controlled Trial with Nabilone [D] . Sherman, Chelsea. 2018

机译：研究中度至重度阿尔茨海默氏病患者的营养状况，该患者参加了纳比隆的随机对照试验
6. The Alzheimers Prevention Initiative Autosomal-Dominant Alzheimers Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimers disease including a placebo-treated noncarrier cohort [O] . Pierre N. Tariot, Francisco Lopera, Jessica B. Langbaum, 2018

机译：阿尔茨海默氏病预防计划常染色体显性阿尔茨海默氏病试验：在临床前PSEN1 E280A突变携带者中使用克雷珠单抗与安慰剂的研究以评估在常染色体显性阿尔茨海默氏病（包括安慰剂治疗的非携带者队列）中的疗效和安全性
7. The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors [O] . George T. Grossberg, Facundo Manes, Ricardo F. Allegri, 2013

机译：每日一次美金刚胺（28 mg）的安全性，耐受性和功效：接受胆碱酯酶抑制剂的中重度阿尔茨海默氏病患者的多国，随机，双盲，安慰剂对照试验

Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

著录项

相似文献

相关主题

期刊订阅